{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T12:05:29Z","timestamp":1789387529789,"version":"build-2803163510"},"reference-count":39,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2022,9,26]],"date-time":"2022-09-26T00:00:00Z","timestamp":1664150400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"Swiss National Research Foundation","award":["320030-120686"],"award-info":[{"award-number":["320030-120686"]}]},{"name":"Swiss National Research Foundation","award":["324730-144064"],"award-info":[{"award-number":["324730-144064"]}]},{"name":"Swiss National Research Foundation","award":["320030-173211"],"award-info":[{"award-number":["320030-173211"]}]},{"name":"Swiss National Research Foundation","award":["320030-200602"],"award-info":[{"award-number":["320030-200602"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,1,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Several psychotropic drugs can induce weight gain and metabolic alterations. The authors compared metabolic evolutions of patients switching versus continuing psychotropic treatments with different risk profiles.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients either switched from a high- to a medium- (N\u2005=\u200536) or low-risk drug (N\u2005=\u200527), from a medium- to a low-risk drug (N\u2005=\u200571), or to a same-risk drug (N\u2005=\u200561). Controls were kept using either a high- (N\u2005=\u200535), medium- (N\u2005=\u2005155), or low-risk drug (N\u2005=\u200547). The evolution over 2 years of weight and metabolic parameters was analyzed using linear mixed-effect models, also examining the influence of polygenic risk scores for body mass index (BMI) or BMI and psychiatric disorders.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Study Results<\/jats:title>\n                    <jats:p>High-, medium-, or low-risk controls gained on average 1.32%, 0.42%, and 0.36% more weight per month than patients switching from or within these risk categories (P\u2005&amp;lt;\u2005.001, P\u2005&amp;lt;\u2005.001, and P\u2005=\u2005.003, respectively). High-to-high or high-to-medium switches resulted in a greater weight increase than switching to lower-risk categories (+0.77% and +\u20050.39% respectively, P\u2005&amp;lt;\u2005.001). No difference was found between switching medium-to-medium and medium-to-low (P\u2005\u2248\u20051). Switching high-to-low resulted in 10% weight loss after 2 years, with the greatest loss occurring the first 6 months after the switch. Compared with high-risk controls, lower total cholesterol (\u22120.27 mmol\/l, P\u2005=\u2005.043) in the high-to-low group, and lower glucose (\u22120.44 mmol\/l, P\u2005=\u2005.032) and systolic blood pressure (\u22125.50 mmHg, P\u2005=\u2005.034) in the low-to-low group were found. Polygenic scores were not associated with weight changes in controls or after switching.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Psychotropic switches to a lower- or same-risk drug can attenuate weight gain, with only switching high to low resulting in weight loss.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/schbul\/sbac133","type":"journal-article","created":{"date-parts":[[2022,9,5]],"date-time":"2022-09-05T16:47:20Z","timestamp":1662396440000},"page":"24-33","source":"Crossref","is-referenced-by-count":7,"title":["Evolutions of Metabolic Parameters Following Switches of Psychotropic Drugs: A Longitudinal Cohort Study"],"prefix":"10.1093","volume":"49","author":[{"given":"Marianna","family":"Piras","sequence":"first","affiliation":[{"name":"Unit of Pharmacogenetics and Clinical Psychopharmacology, Centre for Psychiatric Neuroscience, Department of Psychiatry, Lausanne University Hospital, University of Lausanne , Prilly , Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Setareh","family":"Ranjbar","sequence":"additional","affiliation":[{"name":"Center for Psychiatric Epidemiology and Psychopathology, Department of Psychiatry, Lausanne University Hospital, University of Lausanne , Prilly , Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nermine","family":"Laaboub","sequence":"additional","affiliation":[{"name":"Unit of Pharmacogenetics and Clinical Psychopharmacology, Centre for Psychiatric Neuroscience, Department of Psychiatry, Lausanne University Hospital, University of Lausanne , Prilly , Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Grosu","sequence":"additional","affiliation":[{"name":"Unit of Pharmacogenetics and Clinical Psychopharmacology, Centre for Psychiatric Neuroscience, Department of Psychiatry, Lausanne University Hospital, University of Lausanne , Prilly , Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franziska","family":"Gamma","sequence":"additional","affiliation":[{"name":"Les Toises Psychiatry and Psychotherapy Center , Lausanne , Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerstin Jessica","family":"Plessen","sequence":"additional","affiliation":[{"name":"Service of Child and Adolescent Psychiatry, Department of Psychiatry, Lausanne University Hospital, University of Lausanne , Prilly , Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armin","family":"von Gunten","sequence":"additional","affiliation":[{"name":"Service of Old Age Psychiatry, Department of Psychiatry, Lausanne University Hospital, University of Lausanne , Prilly , Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Conus","sequence":"additional","affiliation":[{"name":"Service of General Psychiatry, Department of Psychiatry, Lausanne University Hospital, University of Lausanne , Prilly , Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chin Bin","family":"Eap","sequence":"additional","affiliation":[{"name":"Unit of Pharmacogenetics and Clinical Psychopharmacology, Centre for Psychiatric Neuroscience, Department of Psychiatry, Lausanne University Hospital, University of Lausanne , Prilly , Switzerland"},{"name":"School of Pharmaceutical Sciences, University of Geneva, University of Lausanne , Geneva , Switzerland"},{"name":"Center for Research and Innovation in Clinical Pharmaceutical Sciences, University of Lausanne , Lausanne , Switzerland"},{"name":"Institute of Pharmaceutical Sciences of Western Switzerland, University of Geneva, University of Lausanne , Geneva , Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,9,26]]},"reference":[{"issue":"2","key":"2023010315541868500_CIT0001","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1097\/YCO.0b013e32835035ca","article-title":"Life expectancy and cardiovascular mortality in persons with schizophrenia","volume":"25","author":"Laursen","year":"2012","journal-title":"Curr Opin Psychiatry"},{"issue":"6","key":"2023010315541868500_CIT0002","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1001\/archgenpsychiatry.2011.2","article-title":"Systematic review of early cardiometabolic outcomes of the first treated episode of psychosis","volume":"68","author":"Foley","year":"2011","journal-title":"Arch Gen Psychiatry"},{"issue":"9","key":"2023010315541868500_CIT0003","doi-asserted-by":"crossref","first-page":"3232","DOI":"10.2337\/db13-0430","article-title":"Antipsychotic-induced insulin resistance and postprandial hormonal dysregulation independent of weight gain or psychiatric disease","volume":"62","author":"Teff","year":"2013","journal-title":"Diabetes"},{"issue":"10","key":"2023010315541868500_CIT0004","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1176\/ajp.2006.163.10.1821","article-title":"Hyperlipidemia following treatment with antipsychotic medications","volume":"163","author":"Olfson","year":"2006","journal-title":"Am J Psychiatry"},{"issue":"11","key":"2023010315541868500_CIT0005","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.3390\/cells8111336","article-title":"Second-generation antipsychotics and dysregulation of glucose metabolism: beyond weight gain","volume":"8","author":"Grajales","year":"2019","journal-title":"Cells"},{"issue":"1","key":"2023010315541868500_CIT0006","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/S2215-0366(19)30416-X","article-title":"Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis","volume":"7","author":"Pillinger","year":"2020","journal-title":"Lancet Psychiatry"},{"issue":"5","key":"2023010315541868500_CIT0007","doi-asserted-by":"crossref","first-page":"117","DOI":"10.3810\/pgm.2013.09.2706","article-title":"Weight considerations in psychotropic drug prescribing and switching","volume":"125","author":"Hasnain","year":"2013","journal-title":"Postgrad Med"},{"issue":"2","key":"2023010315541868500_CIT0008","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1097\/YIC.0b013e328333ac1b","article-title":"Efficacy of valproate versus lithium in mania or mixed mania: a randomized, open 12-week trial","volume":"25","author":"Bowden","year":"2010","journal-title":"Int Clin Psychopharmacol"},{"key":"2023010315541868500_CIT0009","doi-asserted-by":"crossref","DOI":"10.1515\/hmbci-2017-0065","article-title":"Cardiometabolic effects of psychotropic medications.","volume-title":"Horm MolBiol Clin Investig.","author":"Abosi","year":"2018"},{"issue":"3","key":"2023010315541868500_CIT0010","first-page":"125","article-title":"Valproate-induced insulin resistance and obesity in children","volume":"71","author":"Verrotti","year":"2009","journal-title":"Horm Res"},{"key":"2023010315541868500_CIT0011","volume-title":"Second-Generation Antidepressants in the Pharmacologic Treatment of Adult Depression: An Update of the 2007 Comparative Effectiveness Review. Comparative Effectiveness Review No. 48","author":"Gartlehner","year":"2011"},{"key":"2023010315541868500_CIT0012","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.ejphar.2018.12.003","article-title":"Antipsychotics-induced metabolic alterations: recounting the mechanistic insights, therapeutic targets and pharmacological alternatives","volume":"844","author":"Singh","year":"2019","journal-title":"Eur J Pharmacol"},{"issue":"2","key":"2023010315541868500_CIT0013","first-page":"109","article-title":"Cardiometabolic consequences of therapy for chronic schizophrenia using second-generation antipsychotic agents in a medicaid population: clinical and economic evaluation","volume":"38","author":"Ward","year":"2013","journal-title":"P T"},{"issue":"6","key":"2023010315541868500_CIT0014","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/j.jpsychires.2008.11.001","article-title":"Antipsychotic-induced body weight gain: predictors and a systematic categorization of the long-term weight course","volume":"43","author":"Gebhardt","year":"2009","journal-title":"J Psychiatr Res"},{"issue":"4","key":"2023010315541868500_CIT0015","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s00213-002-1344-3","article-title":"Switching patients to aripiprazole from other antipsychotic agents: a multicenter randomized study","volume":"166","author":"Casey","year":"2003","journal-title":"Psychopharmacology (Berl)"},{"issue":"12","key":"2023010315541868500_CIT0016","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1016\/j.clinthera.2005.12.005","article-title":"Effects of switching from olanzapine to risperidone on the prevalence of the metabolic syndrome in overweight or obese patients with schizophrenia or schizoaffective disorder: analysis of a multicenter, rater-blinded, open-label study","volume":"27","author":"Meyer","year":"2005","journal-title":"Clin Ther"},{"issue":"1","key":"2023010315541868500_CIT0017","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.schres.2003.09.016","article-title":"Weight decline in patients switching from olanzapine to quetiapine","volume":"70","author":"Gupta","year":"2004","journal-title":"Schizophr Res"},{"issue":"1","key":"2023010315541868500_CIT0018","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1186\/s12888-020-02523-1","article-title":"Switching to Lurasidone following 12 months of treatment with Risperidone: results of a 6-month, open-label study","volume":"20","author":"Mattingly","year":"2020","journal-title":"BMC Psychiatry"},{"issue":"5","key":"2023010315541868500_CIT0019","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1097\/WNF.0b013e3182a31ec0","article-title":"Effectiveness and tolerability of switching to aripiprazole from risperidone in subjects with autism spectrum disorders: a prospective open-label study","volume":"36","author":"Ishitobi","year":"2013","journal-title":"Clin Neuropharmacol"},{"issue":"8","key":"2023010315541868500_CIT0020","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.4088\/JCP.v65n0809","article-title":"Safety and efficacy of long-acting risperidone in schizophrenia: a 12-week, multicenter, open-label study in stable patients switched from typical and atypical oral antipsychotics","volume":"65","author":"Lindenmayer","year":"2004","journal-title":"J Clin Psychiatry"},{"issue":"4","key":"2023010315541868500_CIT0021","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1093\/schbul\/sbaa191","article-title":"Does switching antipsychotics ameliorate weight gain in patients with severe mental illness? A systematic review and meta-analysis","volume":"47","author":"Siskind","year":"2021","journal-title":"Schizophr Bull"},{"issue":"9","key":"2023010315541868500_CIT0022","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1176\/appi.ajp.2011.10111609","article-title":"A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems (CAMP)","volume":"168","author":"Stroup","year":"2011","journal-title":"Am J Psychiatry"},{"issue":"5","key":"2023010315541868500_CIT0023","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1097\/WNF.0b013e31819a68b5","article-title":"Effectiveness of switching to aripiprazole from atypical antipsychotics in patients with schizophrenia","volume":"32","author":"Kim","year":"2009","journal-title":"Clin Neuropharmacol"},{"key":"2023010315541868500_CIT0024","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/1744-859X-9-35","article-title":"A 64-week, multicenter, open-label study of aripiprazole effectiveness in the management of patients with schizophrenia or schizoaffective disorder in a general psychiatric outpatient setting","volume":"9","author":"Hsieh","year":"2010","journal-title":"Ann Gen Psychiatry"},{"key":"2023010315541868500_CIT0025","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.jad.2020.03.030","article-title":"Comparative efficacy and tolerability of pharmacological treatments for the treatment of acute bipolar depression: a systematic review and network meta-analysis","volume":"269","author":"Bahji","year":"2020","journal-title":"J Affect Disord"},{"issue":"10173","key":"2023010315541868500_CIT0026","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/S0140-6736(18)31793-8","article-title":"Pharmacological treatments for generalised anxiety disorder: a systematic review and network meta-analysis","volume":"393","author":"Slee","year":"2019","journal-title":"Lancet"},{"issue":"11","key":"2023010315541868500_CIT0027","doi-asserted-by":"crossref","first-page":"e1417","DOI":"10.4088\/JCP.14m09358","article-title":"Importance of early weight changes to predict long-term weight gain during psychotropic drug treatment","volume":"76","author":"Vandenberghe","year":"2015","journal-title":"J Clin Psychiatry"},{"issue":"12","key":"2023010315541868500_CIT0028","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1007\/s40262-018-0664-3","article-title":"Clinical pharmacokinetics of atypical antipsychotics: an update","volume":"57","author":"Mauri","year":"2018","journal-title":"Clin Pharmacokinet."},{"issue":"1","key":"2023010315541868500_CIT0029","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1186\/s12888-016-1049-5","article-title":"Metformin in prevention and treatment of antipsychotic induced weight gain: a systematic review and meta-analysis","volume":"16","author":"de Silva","year":"2016","journal-title":"BMC Psychiatry"},{"issue":"3","key":"2023010315541868500_CIT0030","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1097\/WNF.0b013e3181d52b85","article-title":"Effectiveness of switching from aripiprazole to ziprasidone in patients with schizophrenia","volume":"33","author":"Kim","year":"2010","journal-title":"Clin Neuropharmacol"},{"issue":"2","key":"2023010315541868500_CIT0031","doi-asserted-by":"crossref","first-page":"e0244944","DOI":"10.1371\/journal.pone.0244944","article-title":"Antipsychotics result in more weight gain in antipsychotic naive patients than in patients after antipsychotic switch and weight gain is irrespective of psychiatric diagnosis: a meta-analysis","volume":"16","author":"Bak","year":"2021","journal-title":"PLoS One"},{"issue":"3","key":"2023010315541868500_CIT0032","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1097\/01.jcp.0000161501.65890.22","article-title":"Association between early and rapid weight gain and change in weight over one year of olanzapine therapy in patients with schizophrenia and related disorders","volume":"25","author":"Kinon","year":"2005","journal-title":"J Clin Psychopharmacol"},{"issue":"4","key":"2023010315541868500_CIT0033","doi-asserted-by":"crossref","first-page":"154","DOI":"10.3810\/pgm.2012.07.2577","article-title":"Weight gain and glucose dysregulation with second-generation antipsychotics and antidepressants: a review for primary care physicians","volume":"124","author":"Hasnain","journal-title":"Postgrad Med"},{"key":"2023010315541868500_CIT0034","first-page":"100","article-title":"Weight regain prevention.","volume-title":"Clin Diabetes.","author":"Garcia Ulen","year":"2008"},{"issue":"2","key":"2023010315541868500_CIT0035","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1038\/nrendo.2011.156","article-title":"Metabolic and cardiovascular adverse effects associated with antipsychotic drugs","volume":"8","author":"De Hert","year":"2011","journal-title":"Nat Rev Endocrinol"},{"issue":"2","key":"2023010315541868500_CIT0036","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.pnpbp.2010.12.003","article-title":"A retrospective comparison of BMI changes and the potential risk factors among schizophrenic inpatients treated with aripiprazole, olanzapine, quetiapine or risperidone","volume":"35","author":"Lee","year":"2011","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry."},{"issue":"4","key":"2023010315541868500_CIT0037","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1111\/bcpt.13715","article-title":"Olanzapine-associated dose-dependent alterations for weight and metabolic parameters in a prospective cohort","volume":"130","author":"Schoretsanitis","year":"2022","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"6","key":"2023010315541868500_CIT0038","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1055\/a-1525-2820","article-title":"Effect of quetiapine, from low to high dose, on weight and metabolic traits: results from a prospective cohort study","volume":"54","author":"Dubath","year":"2021","journal-title":"Pharmacopsychiatry"},{"issue":"4","key":"2023010315541868500_CIT0039","doi-asserted-by":"crossref","first-page":"21m14110","DOI":"10.4088\/JCP.21m14110","article-title":"Daily dose effects of risperidone on weight and other metabolic parameters: a prospective cohort study.","volume":"83","author":"Piras","year":"2022","journal-title":"J Clin Psychiatry."}],"container-title":["Schizophrenia Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/schizophreniabulletin\/article-pdf\/49\/1\/24\/48482734\/sbac133.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/schizophreniabulletin\/article-pdf\/49\/1\/24\/48482734\/sbac133.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,3]],"date-time":"2023-01-03T10:58:33Z","timestamp":1672743513000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/schizophreniabulletin\/article\/49\/1\/24\/6717852"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,26]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,9,26]]},"published-print":{"date-parts":[[2023,1,3]]}},"URL":"https:\/\/doi.org\/10.1093\/schbul\/sbac133","relation":{},"ISSN":["0586-7614","1745-1701"],"issn-type":[{"value":"0586-7614","type":"print"},{"value":"1745-1701","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,1,1]]},"published":{"date-parts":[[2022,9,26]]}}}